Group Raises Safety Concerns Over Hormone Treatment

Law360, New York (August 23, 2006, 12:00 AM EDT) -- A women’s health group has asked the U.S. Food and Drug Administration to put a stop to sales of estrogen and testosterone combinations made by two pharmaceutical companies used to alleviate hot flashes associated with menopause.

The National Women’s Health Network said Tuesday that it petitioned Andrew Von Eschenbach, the acting commissioner at the FDA, to halt sales of Solvay SA’s Estratest and Breckenridge Pharmaceutical’s Syntest, stating the hormone treatments lack evidence that they are safe.

“Solvay and Breckenridge continue to market Estratest and Syntest…even though...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.